hi Peony, I can understand your view on vivagel sales. It’s really hard to forecast short term. But as the product is released in more and more countries sales will increase. We have a global product being rolled out with millions of potential repeat customers. It’s a nice position to be in.
regardless, DEP is the big item and we have phase II results due in the first half.
SPL Price at posting:
$1.18 Sentiment: Buy Disclosure: Held
